FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 338:962-968 April 2, 1998 Number 14 Next

	Full Text PDF Editorial by Hehlmann, R. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Chronic myeloid leukemia can be cured by marrow transplantation from an HLA-identical sibling donor. The use of transplants from unrelated donors is an option for the 70 percent of patients without an HLA-identical sibling, but the morbidity and mortality associated with such transplants have been cause for concern. We analyzed the safety and efficacy of transplants from unrelated donors for the treatment of chronic myeloid leukemia and identified variables that predict a favorable outcome.

Methods Between May 1985 and December 1994, 196 patients with Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase received marrow transplants from unrelated donors.

Results The median follow-up was 5 years (range, 1.2 to 10.1). Graft failure occurred in 5 percent of patients who could be evaluated. Acute graft-versus-host disease of grade III or IV severity was observed in 35 percent of patients who received HLA-matched transplants, and the estimated cumulative incidence of relapse at five years was 10 percent. The Kaplan–Meier estimate of survival at five years was 57 percent. Survival was adversely affected by an interval from diagnosis to transplantation of one year or more, an HLA-DRB1 mismatch, a high body-weight index, and an age of more than 50 years. Survival was improved by the prophylactic use of fluconazole and ganciclovir. The Kaplan–Meier estimate of survival at five years was 74 percent (95 percent confidence interval, 62 to 86 percent) for patients who were 50 years of age or younger who received a transplant from an HLA-matched donor within one year after diagnosis.

Conclusions Transplantation of marrow from an HLA-matched, unrelated donor is safe and effective therapy for selected patients with chronic myeloid leukemia.

Source Information

From the Fred Hutchinson Cancer Research Center (J.A.H., T.A.G., P.J.M., F.A., T.R.C., R.A.C., E.W.P., J.R., J.E.S., R.F.S., K.M.S., C.A.), the Veterans Affairs Medical Center (T.R.C.), and the University of Washington School of Medicine (J.A.H., P.J.M., F.A., T.R.C., E.W.P., J.R., J.E.S., R.F.S., K.M.S., C.A.) — all in Seattle.

Address reprint requests to Dr. Hansen at the Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N., Seattle, WA 98109-1024.

Full Text of this Article

This article has been cited by other articles:

• Atsuta, Y., Suzuki, R., Nagamura-Inoue, T., Taniguchi, S., Takahashi, S., Kai, S., Sakamaki, H., Kouzai, Y., Kasai, M., Fukuda, T., Azuma, H., Takanashi, M., Okamoto, S., Tsuchida, M., Kawa, K., Morishima, Y., Kodera, Y., Kato, S., for the Japan Marrow Donor Program and the Japan C, (2009). Disease-specific analyses of unrelated cord blood transplantation compared with unrelated bone marrow transplantation in adult patients with acute leukemia. Blood 113: 1631-1638 [Abstract] [Full Text]  
• Lee, S. J., Kukreja, M., Wang, T., Giralt, S. A., Szer, J., Arora, M., Woolfrey, A. E., Cervantes, F., Champlin, R. E., Gale, R. P., Halter, J., Keating, A., Marks, D. I., McCarthy, P. L., Olavarria, E., Stadtmauer, E. A., Abecasis, M., Gupta, V., Khoury, H. J., George, B., Hale, G. A., Liesveld, J. L., Rizzieri, D. A., Antin, J. H., Bolwell, B. J., Carabasi, M. H., Copelan, E., Ilhan, O., Litzow, M. R., Schouten, H. C., Zander, A. R., Horowitz, M. M., Maziarz, R. T. (2008). Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. Blood 112: 3500-3507 [Abstract] [Full Text]  
• Ramirez, P., DiPersio, J. F. (2008). Therapy Options in Imatinib Failures. The Oncologist 13: 424-434 [Abstract] [Full Text]  
• Kawase, T., Morishima, Y., Matsuo, K., Kashiwase, K., Inoko, H., Saji, H., Kato, S., Juji, T., Kodera, Y., Sasazuki, T., for The Japan Marrow Donor Program, (2007). High-risk HLA allele mismatch combinations responsible for severe acute graft-versus-host disease and implication for its molecular mechanism. Blood 110: 2235-2241 [Abstract] [Full Text]  
• Hehlmann, R., Berger, U., Pfirrmann, M., Heimpel, H., Hochhaus, A., Hasford, J., Kolb, H.-J., Lahaye, T., Maywald, O., Reiter, A., Hossfeld, D. K., Huber, C., Loffler, H., Pralle, H., Queisser, W., Tobler, A., Nerl, C., Solenthaler, M., Goebeler, M. E., Griesshammer, M., Fischer, T., Kremers, S., Eimermacher, H., Pfreundschuh, M., Hirschmann, W.-D., Lechner, K., Wassmann, B., Falge, C., Kirchner, H. H., Gratwohl, A., for the Schweizerische Arbeitsgemeinschaft fur Kli, (2007). Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood 109: 4686-4692 [Abstract] [Full Text]  
• Wade, J. A., Katovich Hurley, C., Takemoto, S. K., Thompson, J., Davies, S. M., Fuller, T. C., Rodey, G., Confer, D. L., Noreen, H., Haagenson, M., Kan, F., Klein, J., Eapen, M., Spellman, S., Kollman, C. (2007). HLA mismatching within or outside of cross-reactive groups (CREGs) is associated with similar outcomes after unrelated hematopoietic stem cell transplantation. Blood 109: 4064-4070 [Abstract] [Full Text]  
• Sizzano, F., Dametto, E., Amoroso, A. (2007). Evaluation of Alloreactivity in Responder-Stimulator Pairs by Determination of Gamma Interferon-Producing Cells and Cytotoxic-T-Lymphocyte Precursor Frequencies. CVI 14: 481-483 [Abstract] [Full Text]  
• Oehler, V. G., Gooley, T., Snyder, D. S., Johnston, L., Lin, A., Cummings, C. C., Chu, S., Bhatia, R., Forman, S. J., Negrin, R. S., Appelbaum, F. R., Radich, J. P. (2007). The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. Blood 109: 1782-1789 [Abstract] [Full Text]  
• Steensma, D. P., Richard, R. E. (2007). Myeloproliferative disorders. ASH-SAP 2007: 172-227 [Full Text]  
• Deeg, H. J., O'Donnell, M., Tolar, J., Agarwal, R., Harris, R. E., Feig, S. A., Territo, M. C., Collins, R. H., McSweeney, P. A., Copelan, E. A., Khan, S. P., Woolfrey, A., Storer, B. (2006). Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy. Blood 108: 1485-1491 [Abstract] [Full Text]  
• Quintas-Cardama, A., Cortes, J. E. (2006). Chronic Myeloid Leukemia: Diagnosis and Treatment. Mayo Clin Proc. 81: 973-988 [Abstract] [Full Text]  
• Iacobucci, I., Saglio, G., Rosti, G., Testoni, N., Pane, F., Amabile, M., Poerio, A., Soverini, S., Bassi, S., Cilloni, D., Bassan, R., Breccia, M., Lauria, F., Izzo, B., Merante, S., Frassoni, F., Paolini, S., Montefusco, E., Baccarani, M., Martinelli, G., for the GIMEMA Working Party on Chronic Myeloid Le, (2006). Achieving a Major Molecular Response at the Time of a Complete Cytogenetic Response (CCgR) Predicts a Better Duration of CCgR in Imatinib-Treated Chronic Myeloid Leukemia Patients.. Clin. Cancer Res. 12: 3037-3042 [Abstract] [Full Text]  
• Mauro, M. J., Maziarz, R. T. (2006). Stem Cell Transplantation in Patients With Chronic Myelogenous Leukemia: When Should It Be Used?. Mayo Clin Proc. 81: 404-416 [Abstract] [Full Text]  
• Iacobucci, I., Rosti, G., Amabile, M., Poerio, A., Soverini, S., Cilloni, D., Testoni, N., Abruzzese, E., Montefusco, E., Ottaviani, E., Iuliano, F., Russo, D., Gobbi, M., Alimena, G., Martino, B., Terragna, C., Pane, F., Saglio, G., Baccarani, M., Martinelli, G. (2006). Comparison Between Patients With Philadelphia-Positive Chronic Phase Chronic Myeloid Leukemia Who Obtained a Complete Cytogenetic Response Within 1 Year of Imatinib Therapy and Those Who Achieved Such a Response After 12 Months of Treatment. JCO 24: 454-459 [Abstract] [Full Text]  
• Hess, G., Bunjes, D., Siegert, W., Schwerdtfeger, R., Ledderose, G., Wassmann, B., Kobbe, G., Bornhauser, M., Hochhaus, A., Ullmann, A. J., Kindler, T., Haus, U., Gschaidmeier, H., Huber, C., Fischer, T. (2005). Sustained Complete Molecular Remissions After Treatment With Imatinib-Mesylate in Patients With Failure After Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia: Results of a Prospective Phase II Open-Label Multicenter Study. JCO 23: 7583-7593 [Abstract] [Full Text]  
• Pavletic, S. Z., Khouri, I. F., Haagenson, M., King, R. J., Bierman, P. J., Bishop, M. R., Carston, M., Giralt, S., Molina, A., Copelan, E. A., Ringden, O., Roy, V., Ballen, K., Adkins, D. R., McCarthy, P., Weisdorf, D., Montserrat, E., Anasetti, C. (2005). Unrelated Donor Marrow Transplantation for B-Cell Chronic Lymphocytic Leukemia After Using Myeloablative Conditioning: Results From the Center for International Blood and Marrow Transplant Research. JCO 23: 5788-5794 [Abstract] [Full Text]  
• Chang, G., Orav, E. J., McNamara, T. K., Tong, M.-Y., Antin, J. H. (2005). Psychosocial Function After Hematopoietic Stem Cell Transplantation. Psychosomatics 46: 34-40 [Abstract] [Full Text]  
• Albert, M. H., Yu, X.-Z., Martin, P. J., Anasetti, C. (2005). Prevention of lethal acute GVHD with an agonistic CD28 antibody and rapamycin. Blood 105: 1355-1361 [Abstract] [Full Text]  
• Ilaria, R. L. Jr. (2005). Pathobiology of Lymphoid and Myeloid Blast Crisis and Management Issues. ASH Education Book 2005: 188-194 [Abstract] [Full Text]  
• Takahashi, S., Iseki, T., Ooi, J., Tomonari, A., Takasugi, K., Shimohakamada, Y., Yamada, T., Uchimaru, K., Tojo, A., Shirafuji, N., Kodo, H., Tani, K., Takahashi, T., Yamaguchi, T., Asano, S. (2004). Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies. Blood 104: 3813-3820 [Abstract] [Full Text]  
• Laughlin, M. J., Eapen, M., Rubinstein, P., Wagner, J. E., Zhang, M.-J., Champlin, R. E., Stevens, C., Barker, J. N., Gale, R. P., Lazarus, H. M., Marks, D. I., van Rood, J. J., Scaradavou, A., Horowitz, M. M. (2004). Outcomes after Transplantation of Cord Blood or Bone Marrow from Unrelated Donors in Adults with Leukemia. NEJM 351: 2265-2275 [Abstract] [Full Text]  
• Rocha, V., Labopin, M., Sanz, G., Arcese, W., Schwerdtfeger, R., Bosi, A., Jacobsen, N., Ruutu, T., de Lima, M., Finke, J., Frassoni, F., Gluckman, E., the Acute Leukemia Working Party of European Blood, (2004). Transplants of Umbilical-Cord Blood or Bone Marrow from Unrelated Donors in Adults with Acute Leukemia. NEJM 351: 2276-2285 [Abstract] [Full Text]  
• Robien, K., Ulrich, C. M., Bigler, J., Yasui, Y., Gooley, T., Bruemmer, B., Potter, J. D., Radich, J. P. (2004). Methylenetetrahydrofolate Reductase Genotype Affects Risk of Relapse after Hematopoietic Cell Transplantation for Chronic Myelogenous Leukemia. Clin. Cancer Res. 10: 7592-7598 [Abstract] [Full Text]  
• Petersdorf, E. W., Anasetti, C., Martin, P. J., Gooley, T., Radich, J., Malkki, M., Woolfrey, A., Smith, A., Mickelson, E., Hansen, J. A. (2004). Limits of HLA mismatching in unrelated hematopoietic cell transplantation. Blood 104: 2976-2980 [Abstract] [Full Text]  
• Chang, G., Orav, E. J., Tong, M.-Y., Antin, J. H. (2004). Predictors of 1-Year Survival Assessed at the Time of Bone Marrow Transplantation. Psychosomatics 45: 378-385 [Abstract] [Full Text]  
• Flomenberg, N., Baxter-Lowe, L. A., Confer, D., Fernandez-Vina, M., Filipovich, A., Horowitz, M., Hurley, C., Kollman, C., Anasetti, C., Noreen, H., Begovich, A., Hildebrand, W., Petersdorf, E., Schmeckpeper, B., Setterholm, M., Trachtenberg, E., Williams, T., Yunis, E., Weisdorf, D. (2004). Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood 104: 1923-1930 [Abstract] [Full Text]  
• Kantarjian, H. M., Cortes, J. E., O'Brien, S., Luthra, R., Giles, F., Verstovsek, S., Faderl, S., Thomas, D., Garcia-Manero, G., Rios, M. B., Shan, J., Jones, D., Talpaz, M. (2004). Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-{alpha}. Blood 104: 1979-1988 [Abstract] [Full Text]  
• Lee, S. J., Zahrieh, D., Agura, E., MacMillan, M. L., Maziarz, R. T., McCarthy, P. L. Jr, Ho, V. T., Cutler, C., Alyea, E. P., Antin, J. H., Soiffer, R. J. (2004). Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. Blood 104: 1559-1564 [Abstract] [Full Text]  
• Stone, R. M. (2004). Optimizing Treatment of Chronic Myeloid Leukemia: A Rational Approach. The Oncologist 9: 259-270 [Abstract] [Full Text]  
• Robien, K., Schubert, M. M., Bruemmer, B., Lloid, M. E., Potter, J. D., Ulrich, C. M. (2004). Predictors of Oral Mucositis in Patients Receiving Hematopoietic Cell Transplants for Chronic Myelogenous Leukemia. JCO 22: 1268-1275 [Abstract] [Full Text]  
• Boeckh, M., Nichols, W. G. (2004). The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood 103: 2003-2008 [Abstract] [Full Text]  
• Marr, K. A., Leisenring, W., Crippa, F., Slattery, J. T., Corey, L., Boeckh, M., McDonald, G. B. (2004). Cyclophosphamide metabolism is affected by azole antifungals. Blood 103: 1557-1559 [Abstract] [Full Text]  
• Maris, M. B., Niederwieser, D., Sandmaier, B. M., Storer, B., Stuart, M., Maloney, D., Petersdorf, E., McSweeney, P., Pulsipher, M., Woolfrey, A., Chauncey, T., Agura, E., Heimfeld, S., Slattery, J., Hegenbart, U., Anasetti, C., Blume, K., Storb, R. (2003). HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood 102: 2021-2030 [Abstract] [Full Text]  
• Deininger, M. W. N., Druker, B. J. (2003). Specific Targeted Therapy of Chronic Myelogenous Leukemia with Imatinib. Pharmacol. Rev. 55: 401-423 [Abstract] [Full Text]  
• Antin, J. H., Kim, H. T., Cutler, C., Ho, V. T., Lee, S. J., Miklos, D. B., Hochberg, E. P., Wu, C. J., Alyea, E. P., Soiffer, R. J. (2003). Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood 102: 1601-1605 [Abstract] [Full Text]  
• Cwynarski, K., Roberts, I. A. G., Iacobelli, S., van Biezen, A., Brand, R., Devergie, A., Vossen, J. M., Aljurf, M., Arcese, W., Locatelli, F., Dini, G., Niethammer, D., Niederwieser, D., Apperley, J. F. (2003). Stem cell transplantation for chronic myeloid leukemia in children. Blood 102: 1224-1231 [Abstract] [Full Text]  
• Ottinger, H. D., Ferencik, S., Beelen, D. W., Lindemann, M., Peceny, R., Elmaagacli, A. H., Husing, J., Grosse-Wilde, H. (2003). Hematopoietic stem cell transplantation: contrasting the outcome of transplantations from HLA-identical siblings, partially HLA-mismatched related donors, and HLA-matched unrelated donors. Blood 102: 1131-1137 [Abstract] [Full Text]  
• Grewal, S. S., Barker, J. N., Davies, S. M., Wagner, J. E. (2003). Unrelated donor hematopoietic cell transplantation: marrow or umbilical cord blood?. Blood 101: 4233-4244 [Full Text]  
• Cortes, J. E., Talpaz, M., Giles, F., O'Brien, S., Rios, M. B., Shan, J., Garcia-Manero, G., Faderl, S., Thomas, D. A., Wierda, W., Ferrajoli, A., Jeha, S., Kantarjian, H. M. (2003). Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood 101: 3794-3800 [Abstract] [Full Text]  
• McDonald, G. B., Slattery, J. T., Bouvier, M. E., Ren, S., Batchelder, A. L., Kalhorn, T. F., Schoch, H. G., Anasetti, C., Gooley, T. (2003). Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood 101: 2043-2048 [Abstract] [Full Text]  
• Niederwieser, D., Maris, M., Shizuru, J. A., Petersdorf, E., Hegenbart, U., Sandmaier, B. M., Maloney, D. G., Storer, B., Lange, T., Chauncey, T., Deininger, M., Ponisch, W., Anasetti, C., Woolfrey, A., Little, M.-T., Blume, K. G., McSweeney, P. A., Storb, R. F. (2003). Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 101: 1620-1629 [Abstract] [Full Text]  
• Lang, P., Handgretinger, R., Niethammer, D., Schlegel, P. G., Schumm, M., Greil, J., Bader, P., Engel, C., Scheel-Walter, H., Eyrich, M., Klingebiel, T. (2003). Transplantation of highly purified CD34+ progenitor cells from unrelated donors in pediatric leukemia. Blood 101: 1630-1636 [Abstract] [Full Text]  
• Finke, J., Schmoor, C., Lang, H., Potthoff, K., Bertz, H. (2003). Matched and Mismatched Allogeneic Stem-Cell Transplantation From Unrelated Donors Using Combined Graft-Versus-Host Disease Prophylaxis Including Rabbit Anti-T Lymphocyte Globulin. JCO 21: 506-513 [Abstract] [Full Text]  
• Boeckh, M., Leisenring, W., Riddell, S. R., Bowden, R. A., Huang, M.-L., Myerson, D., Stevens-Ayers, T., Flowers, M. E. D., Cunningham, T., Corey, L. (2003). Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 101: 407-414 [Abstract] [Full Text]  
• Melo, J. V., Hughes, T. P., Apperley, J. F. (2003). Chronic Myeloid Leukemia. ASH Education Book 2003: 132-152 [Abstract] [Full Text]  
• Marr, K. A., Carter, R. A., Boeckh, M., Martin, P., Corey, L. (2002). Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 100: 4358-4366 [Abstract] [Full Text]  
• Tan, P., Mitchell, D. A., Buss, T. N., Holmes, M. A., Anasetti, C., Foote, J. (2002). "Superhumanized" Antibodies: Reduction of Immunogenic Potential by Complementarity-Determining Region Grafting with Human Germline Sequences: Application to an Anti-CD28. J. Immunol. 169: 1119-1125 [Abstract] [Full Text]  
• Ablashi, D. V., Chatlynne, L. G., Whitman, J. E. Jr., Cesarman, E. (2002). Spectrum of Kaposi's Sarcoma-Associated Herpesvirus, or Human Herpesvirus 8, Diseases. Clin. Microbiol. Rev. 15: 439-464 [Abstract] [Full Text]  
• Kantarjian, H. M., Talpaz, M., O'Brien, S., Smith, T. L., Giles, F. J., Faderl, S., Thomas, D. A., Garcia-Manero, G., Issa, J.-P. J., Andreeff, M., Kornblau, S. M., Koller, C., Beran, M., Keating, M., Rios, M. B., Shan, J., Resta, D., Capdeville, R., Hayes, K., Albitar, M., Freireich, E. J., Cortes, J. E. (2002). Imatinib Mesylate for Philadelphia Chromosome-positive, Chronic-Phase Myeloid Leukemia after Failure of Interferon-{alpha}: Follow-Up Results. Clin. Cancer Res. 8: 2177-2187 [Abstract] [Full Text]  
• Morishima, Y., Sasazuki, T., Inoko, H., Juji, T., Akaza, T., Yamamoto, K., Ishikawa, Y., Kato, S., Sao, H., Sakamaki, H., Kawa, K., Hamajima, N., Asano, S., Kodera, Y. (2002). The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. Blood 99: 4200-4206 [Abstract] [Full Text]  
• Copelan, E. A., Goldman, J. M., Druker, B. J. (2002). Treatment options in chronic myelogenous leukemia. Blood 99: 3070-3071 [Full Text]  
• Castro-Malaspina, H., Harris, R. E., Gajewski, J., Ramsay, N., Collins, R., Dharan, B., King, R., Deeg, H. J. (2002). Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. Blood 99: 1943-1951 [Abstract] [Full Text]  
• Weisdorf, D. J., Anasetti, C., Antin, J. H., Kernan, N. A., Kollman, C., Snyder, D., Petersdorf, E., Nelson, G., McGlave, P. (2002). Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. Blood 99: 1971-1977 [Abstract] [Full Text]  
• Savage, D. G., Antman, K. H. (2002). Imatinib Mesylate -- A New Oral Targeted Therapy. NEJM 346: 683-693 [Full Text]  
• Elmaagacli, A. H., Basoglu, S., Peceny, R., Trenschel, R., Ottinger, H., Lollert, A., Runde, V., Grosse-Wilde, H., Beelen, D. W., Schaefer, U. W. (2002). Improved disease-free-survival after transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical unrelated donors in patients with first chronic phase chronic myeloid leukemia. Blood 99: 1130-1135 [Abstract] [Full Text]  
• Drobyski, W. R., Klein, J., Flomenberg, N., Pietryga, D., Vesole, D. H., Margolis, D. A., Keever-Taylor, C. A. (2002). Superior survival associated with transplantation of matched unrelated versus one-antigen-mismatched unrelated or highly human leukocyte antigen- disparate haploidentical family donor marrow grafts for the treatment of hematologic malignancies: establishing a treatment algorithm for recipients of alternative donor grafts. Blood 99: 806-814 [Abstract] [Full Text]  
• Druker, B. J., O'Brien, S. G., Cortes, J., Radich, J. (2002). Chronic Myelogenous Leukemia. ASH Education Book 2002: 111-135 [Abstract] [Full Text]  
• Petersdorf, E. W., Hansen, J. A., Martin, P. J., Woolfrey, A., Malkki, M., Gooley, T., Storer, B., Mickelson, E., Smith, A., Anasetti, C. (2001). Major-Histocompatibility-Complex Class I Alleles and Antigens in Hematopoietic-Cell Transplantation. NEJM 345: 1794-1800 [Abstract] [Full Text]  
• Lee, S. J., Klein, J. P., Anasetti, C., Antin, J. H., Loberiza, F. R., Bolwell, B. J., LeMaistre, C. F., Litzow, M. R., Marks, D., Waller, E. K., Matlack, M., Giralt, S., Horowitz, M. M. (2001). The effect of pretransplant interferon therapy on the outcome of unrelated donor hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in first chronic phase. Blood 98: 3205-3211 [Abstract] [Full Text]  
• Petersdorf, E. W., Kollman, C., Hurley, C. K., Dupont, B., Nademanee, A., Begovich, A. B., Weisdorf, D., McGlave, P. (2001). Effect of HLA class II gene disparity on clinical outcome in unrelated donor hematopoietic cell transplantation for chronic myeloid leukemia: the US National Marrow Donor Program Experience. Blood 98: 2922-2929 [Abstract] [Full Text]  
• Bacigalupo, A., Lamparelli, T., Bruzzi, P., Guidi, S., Alessandrino, P. E., di Bartolomeo, P., Oneto, R., Bruno, B., Barbanti, M., Sacchi, N., Van Lint, M. T., Bosi, A. (2001). Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 98: 2942-2947 [Abstract] [Full Text]  
• Bonifazi, F., de Vivo, A., Rosti, G., Guilhot, F., Guilhot, J., Trabacchi, E., Hehlmann, R., Hochhaus, A., Shepherd, P. C. A., Steegmann, J. L., Kluin-Nelemans, H. C., Thaler, J., Simonsson, B., Louwagie, A., Reiffers, J., Mahon, F. X., Montefusco, E., Alimena, G., Hasford, J., Richards, S., Saglio, G., Testoni, N., Martinelli, G., Tura, S., Baccarani, M. (2001). Chronic myeloid leukemia and interferon-alpha : a study of complete cytogenetic responders. Blood 98: 3074-3081 [Abstract] [Full Text]  
• Sanz, G. F., Saavedra, S., Planelles, D., Senent, L., Cervera, J., Barragan, E., Jimenez, C., Larrea, L., Martin, G., Martinez, J., Jarque, I., Moscardo, F., Plume, G., Andreu, R., Regadera, A. I., Garcia, I., Molla, S., Solves, P., de la Rubia, J., Bolufer, P., Benlloch, L., Soler, M. A., Marty, M. L., Sanz, M. A. (2001). Standardized, unrelated donor cord blood transplantation in adults with hematologic malignancies. Blood 98: 2332-2338 [Abstract] [Full Text]  
• Krcmery, V., Huttova, M., Mateicka, F., Laho, L., Jurga, L., Ondrusova, A., Tarekova, Z., Kralinsky, K., Hanzen, J., Liskova, A., Mrazova, M., Sabo, A., Pisarcikova, M., Kovacicova, G., Chovancova, D., Szovenyiova, Z. (2001). Breakthrough fungaemia in neonates and infants caused by Candida albicans and Candida parapsilosis susceptible to fluconazole in vitro. J Antimicrob Chemother 48: 521-525 [Abstract] [Full Text]  
• Kollman, C., Howe, C. W. S., Anasetti, C., Antin, J. H., Davies, S. M., Filipovich, A. H., Hegland, J., Kamani, N., Kernan, N. A., King, R., Ratanatharathorn, V., Weisdorf, D., Confer, D. L. (2001). Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood 98: 2043-2051 [Abstract] [Full Text]  
• Alpdogan, O., Schmaltz, C., Muriglan, S. J., Kappel, B. J., Perales, M.-A., Rotolo, J. A., Halm, J. A., Rich, B. E., van den Brink, M. R. M. (2001). Administration of interleukin-7 after allogeneic bone marrow transplantation improves immune reconstitution without aggravating graft-versus-host disease. Blood 98: 2256-2265 [Abstract] [Full Text]  
• Bunjes, D., Buchmann, I., Duncker, C., Seitz, U., Kotzerke, J., Wiesneth, M., Dohr, D., Stefanic, M., Buck, A., Harsdorf, S. V., Glatting, G., Grimminger, W., Karakas, T., Munzert, G., Dohner, H., Bergmann, L., Reske, S. N. (2001). Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study. Blood 98: 565-572 [Abstract] [Full Text]  
• Ulrich, C. M., Yasui, Y., Storb, R., Schubert, M. M., Wagner, J. L., Bigler, J., Ariail, K. S., Keener, C. L., Li, S., Liu, H., Farin, F. M., Potter, J. D. (2001). Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood 98: 231-234 [Abstract] [Full Text]  
• Laughlin, M. J., Barker, J., Bambach, B., Koc, O. N., Rizzieri, D. A., Wagner, J. E., Gerson, S. L., Lazarus, H. M., Cairo, M., Stevens, C. E., Rubinstein, P., Kurtzberg, J. (2001). Hematopoietic Engraftment and Survival in Adult Recipients of Umbilical-Cord Blood from Unrelated Donors. NEJM 344: 1815-1822 [Abstract] [Full Text]  
• Soiffer, R. J., Weller, E., Alyea, E. P., Mauch, P., Webb, I. L., Fisher, D. C., Freedman, A. S., Schlossman, R. L., Gribben, J., Lee, S., Anderson, K. C., Marcus, K., Stone, R. M., Antin, J. H., Ritz, J. (2001). CD6+ Donor Marrow T-Cell Depletion as the Sole Form of Graft-Versus-Host Disease Prophylaxis in Patients Undergoing Allogeneic Bone Marrow Transplant From Unrelated Donors. JCO 19: 1152-1159 [Abstract] [Full Text]  
• Druker, B. J., Sawyers, C. L., Capdeville, R., Ford, J. M., Baccarani, M., Goldman, J. M. (2001). Chronic Myelogenous Leukemia. ASH Education Book 2001: 87-112 [Abstract] [Full Text]  
• Marr, K. A., Seidel, K., Slavin, M. A., Bowden, R. A., Schoch, H. G., Flowers, M. E. D., Corey, L., Boeckh, M. (2000). Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 96: 2055-2061 [Abstract] [Full Text]  
• Nash, R. A., Antin, J. H., Karanes, C., Fay, J. W., Avalos, B. R., Yeager, A. M., Przepiorka, D., Davies, S., Petersen, F. B., Bartels, P., Buell, D., Fitzsimmons, W., Anasetti, C., Storb, R., Ratanatharathorn, V. (2000). Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 96: 2062-2068 [Abstract] [Full Text]  
• Mielcarek, M., Leisenring, W., Torok-Storb, B., Storb, R. (2000). Graft-versus-host disease and donor-directed hemagglutinin titers after ABO-mismatched related and unrelated marrow allografts: evidence for a graft-versus-plasma cell effect. Blood 96: 1150-1156 [Abstract] [Full Text]  
• Craddock, C., Szydlo, R. M., Klein, J. P., Dazzi, F., Olavarria, E., van Rhee, F., Pocock, C., Cwynarski, K., Apperley, J. F., Goldman, J. M. (2000). Estimating leukemia-free survival after allografting for chronic myeloid leukemia: a new method that takes into account patients who relapse and are restored to complete remission. Blood 96: 86-90 [Abstract] [Full Text]  
• Yu, X.-Z., Bidwell, S. J., Martin, P. J., Anasetti, C. (2000). CD28-Specific Antibody Prevents Graft-Versus-Host Disease in Mice. J. Immunol. 164: 4564-4568 [Abstract] [Full Text]  
• Reddy, V., Moreb, J., Mehta;, P., Dazzi, F., Szydlo, R. M., Goldman, J. M. (2000). Donor lymphocyte infusions for CML: possible effects of age and mobilization. Blood 95: 2994-2995 [Full Text]  
• McGlave, P. B., Shu, X. O., Wen, W., Anasetti, C., Nademanee, A., Champlin, R., Antin, J. H., Kernan, N. A., King, R., Weisdorf, D. J. (2000). Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the National Marrow Donor Program. Blood 95: 2219-2225 [Abstract] [Full Text]  
• Deeg, H. J., Shulman, H. M., Anderson, J. E., Bryant, E. M., Gooley, T. A., Slattery, J. T., Anasetti, C., Fefer, A., Storb, R., Appelbaum, F. R. (2000). Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age. Blood 95: 1188-1194 [Abstract] [Full Text]  
• Kantarjian, H., Melo, J. V., Tura, S., Giralt, S., Talpaz, M. (2000). Chronic Myelogenous Leukemia: Disease Biology and Current and Future Therapeutic Strategies. ASH Education Book 2000: 90-109 [Abstract] [Full Text]  
• Hehlmann, R., Hochhaus, A., Kolb, H.-J., Hasford, J., Gratwohl, A., Heimpel, H., Siegert, W., Finke, J., Ehninger, G., Holler, E., Berger, U., Pfirrmann, M., Muth, A., Zander, A., Fauser, A. A., Heyll, A., Nerl, C., Hossfeld, D. K., Loffler, H., Pralle, H., Tobler, W. Q.{b.}e. a. A. (1999). Interferon-alpha Before Allogeneic Bone Marrow Transplantation in Chronic Myelogenous Leukemia Does Not Affect Outcome Adversely, Provided It Is Discontinued at Least 90 Days Before the Procedure. Blood 94: 3668-3677 [Abstract] [Full Text]  
• Tseng, L.-H., Lin, M.-T., Hansen, J. A., Gooley, T., Pei, J., Smith, A. G., Martin, E. G., Petersdorf, E. W., Martin, P. J. (1999). Correlation Between Disparity for the Minor Histocompatibility Antigen HA-1 and the Development of Acute Graft-Versus-Host Disease After Allogeneic Marrow Transplantation. Blood 94: 2911-2914 [Abstract] [Full Text]  
• Martin, P. J., Rowley, S. D., Anasetti, C., Chauncey, T. R., Gooley, T., Petersdorf, E. W., van Burik, J.-A., Flowers, M. E.D., Storb, R., Appelbaum, F. R., Hansen, J. A. (1999). A Phase I-II Clinical Trial to Evaluate Removal of CD4 Cells and Partial Depletion of CD8 Cells From Donor Marrow for HLA-Mismatched Unrelated Recipients. Blood 94: 2192-2199 [Abstract] [Full Text]  
• Green, A., Clarke, E., Hunt, L., Canterbury, A., Lankester, A., Hale, G., Waldmann, H., Goodman, S., Cornish, J. M., Marks, D. I., Steward, C. G., Oakhill, A., Pamphilon, D. H. (1999). Children With Acute Lymphoblastic Leukemia Who Receive T-Cell-Depleted HLA Mismatched Marrow Allografts From Unrelated Donors Have an Increased Incidence of Primary Graft Failure but a Similar Overall Transplant Outcome. Blood 94: 2236-2246 [Abstract] [Full Text]  
• Silver, R. T., Woolf, S. H., Hehlmann, R., Appelbaum, F. R., Anderson, J., Bennett, C., Goldman, J. M., Guilhot, F., Kantarjian, H. M., Lichtin, A. E., Talpaz, M., Tura, S. (1999). An Evidence-Based Analysis of the Effect of Busulfan, Hydroxyurea, Interferon, and Allogeneic Bone Marrow Transplantation in Treating the Chronic Phase of Chronic Myeloid Leukemia: Developed for the American Society of Hematology. Blood 94: 1517-1536 [Abstract] [Full Text]  
• Faderl, S., Talpaz, M., Estrov, Z., Kantarjian, H. M. (1999). Chronic Myelogenous Leukemia: Biology and Therapy. ANN INTERN MED 131: 207-219 [Abstract] [Full Text]  
• (1999). Monitoring Treatment and Survival in Chronic Myeloid Leukemia. JCO 17: 1858-1858 [Abstract] [Full Text]  
• Sawyers, C. L. (1999). Chronic Myeloid Leukemia. NEJM 340: 1330-1340 [Full Text]  
• Small, T.N., Papadopoulos, E.B., Boulad, F., Black, P., Castro-Malaspina, H., Childs, B.H., Collins, N., Gillio, A., George, D., Jakubowski, A., Heller, G., Fazzari, M., Kernan, N., MacKinnon, S., Szabolcs, P., Young, J.W., O'Reilly, R.J. (1999). Comparison of Immune Reconstitution After Unrelated and Related T-Cell-Depleted Bone Marrow Transplantation: Effect of Patient Age and Donor Leukocyte Infusions. Blood 93: 467-480 [Abstract] [Full Text]  
• Lee, S. J., Anasetti, C., Kuntz, K. M., Patten, J., Antin, J. H., Weeks, J. C. (1998). The Costs and Cost-Effectiveness of Unrelated Donor Bone Marrow Transplantation for Chronic Phase Chronic Myelogenous Leukemia. Blood 92: 4047-4052 [Abstract] [Full Text]  
• Petersdorf, E. W., Gooley, T. A., Anasetti, C., Martin, P. J., Smith, A. G., Mickelson, E. M., Woolfrey, A. E., Hansen, J. A. (1998). Optimizing Outcome After Unrelated Marrow Transplantation by Comprehensive Matching of HLA Class I and II Alleles in the Donor and Recipient. Blood 92: 3515-3520 [Abstract] [Full Text]  
• Morton, A. J., Gooley, T., Hansen, J. A., Appelbaum, F. R., Bruemmer, B., Bjerke, J. W., Clift, R., Martin, P. J., Petersdorf, E. W., Sanders, J. E., Storb, R., Sullivan, K. M., Woolfrey, A., Anasetti, C. (1998). Association Between Pretransplant Interferon-alpha and Outcome After Unrelated Donor Marrow Transplantation for Chronic Myelogenous Leukemia in Chronic Phase. Blood 92: 394-401 [Abstract] [Full Text]  
• (1998). Marrow Transplants from Unrelated Donors in CML. JWatch General 1998: 6-6 [Full Text]  
• Hehlmann, R. (1998). A Chance of Cure for Every Patient with Chronic Myeloid Leukemia?. NEJM 338: 980-982 [Full Text]